Medicare Coverage Center

Spotlight

National Coverage Determination Analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

CMS is following the long-standing national coverage determination process that includes multiple opportunities for the public to participate and submit comments about the proposed topic.

You can submit comments during the public comment periods by visiting the Medicare Coverage Database.

For this National Coverage Determination (NCD), we are pleased to also announce that two National Stakeholder Calls are scheduled. The transcripts from these calls will be considered part of the official record.  Click on the dates below to register.

Meetings Held By CMS on Treatment for Alzheimer’s Disease

CMS is committed to transparency and wants everyone to understand how the agency makes Medicare coverage determinations. Listed below are the names of all organizations the agency has met with regarding monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. This list will be updated throughout the NCD decision process.

Alzheimer’s Association
Biogen
Duke University, Margolis Center for Health Policy
Johns Hopkins University

 


 

 

 

Important Links

Page Last Modified:
11/02/2015 08:44 AM